NanoViricides, Inc. (NNVC) filed a Rare Pediatric Disease Designation (RPDD) application with the U.S. Food and Drug Administration’s Office of Orphan Products Development on April 7 2026 for its host‑mimetic antiviral candidate NV‑387, targeting measles.
The RPDD filing positions NV‑387 to qualify for a Priority Review Voucher (PRV), a valuable incentive that can be sold or transferred for up to $250 million, though recent PRV sales average around $160 million. The designation also provides seven‑year market exclusivity and opens the door to non‑dilutive government funding and accelerated regulatory pathways for a disease that currently has no approved antiviral therapy.
Measles cases have risen globally and in the United States due to declining vaccination rates and vaccine hesitancy, creating a significant unmet medical need. NV‑387 has shown strong efficacy in animal models and is part of NanoViricides’ broad‑spectrum antiviral platform, which also targets RSV, COVID‑19, influenza, and Mpox. The RPDD filing therefore not only advances a potential measles treatment but also strengthens the company’s overall pipeline.
"NV‑387 as an effective drug is expected to be an important tool to fight Measles resurgence in the USA and worldwide, when approved," said Anil R. Diwan, PhD, President and Executive Chairman. "Treating a Measles patient with NV‑387 would help with rapid recovery and eliminate the high morbidity and the rare post‑Measles ‘Immune Amnesia’ effects." CFO Meeta R. Vyas added, "A Rare Pediatric Disease Drug Designation for NV‑387 would help us tremendously in the mission of regulatory development and approval of NV‑387 to treat Measles, by substantially boosting the potential economic benefits and the business case for this indication."
The RPDD filing follows a prior Orphan Drug Designation (ODD) for NV‑387 filed in February 2026. The Rare Pediatric Disease PRV program, re‑authorized by the Consolidated Appropriations Act of 2026, is set to sunset after September 30 2029, meaning the program will no longer award PRVs beyond that date. By securing RPDD now, NanoViricides positions itself to capture the PRV incentive and exclusivity before the program’s expiration, while also advancing a treatment for a disease with a growing global burden.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.